Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RY 103

Next Previous
Drug Profile

RY 103

Alternative Names: NS 101; RY-103

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reyon Pharmaceutical
  • Developer Neuracle Science; Reyon Pharmaceutical
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Sensorineural hearing loss
  • Phase I Alzheimer's disease
  • No development reported Neurodegenerative disorders

Most Recent Events

  • 19 Jan 2026 Phase-I clinical trials in Alzheimer's disease (Parenteral) prior to January 2026 (Neuracle Science pipeline, January 2026)
  • 04 Sep 2025 Reyon Pharmaceutical in collaboration with Hanyang University Seoul Hospital plans a phase IIa trial for Primary progressive aphasia in unknown location (IV, Infusion) in October 2025 (NCT07154485)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Neurodegenerative-disorders(In volunteers) in South Korea (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top